Despite strong CD22 expression on mature B-cells, naked anti-CD22 antibody and ADC all failed to demonstrate significant benefit over standard of care chemoimmunotherapy in patients with CD22+ R/R B-NHL (26, 27). This evidence concerns the gene CD22 and non-Hodgkin lymphoma.